115 related articles for article (PubMed ID: 12642477)
1. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice.
Zhang JY; Yuan JJ; Wang YF; Bible RH; Breau AP
Drug Metab Dispos; 2003 Apr; 31(4):491-501. PubMed ID: 12642477
[TBL] [Abstract][Full Text] [Related]
2. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
Yuan JJ; Yang DC; Zhang JY; Bible R; Karim A; Findlay JW
Drug Metab Dispos; 2002 Sep; 30(9):1013-21. PubMed ID: 12167567
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice.
Jin X; Zhou F; Liu Y; Cheng C; Yao L; Jia Y; Wang G; Zhang J
J Pharm Biomed Anal; 2018 Sep; 158():1-7. PubMed ID: 29843006
[TBL] [Abstract][Full Text] [Related]
4. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Sarapa N; Britto MR; Mainka MB; Parivar K
Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of valdecoxib by microbial cultures.
Keshetti S; Ciddi V
J Microbiol Biotechnol; 2010 Apr; 20(4):809-16. PubMed ID: 20467258
[TBL] [Abstract][Full Text] [Related]
6. Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS.
Hu J; Lv BF; Guo WJ; Wang BW; Miao D; Qiu XJ; Chen XP
Biomed Res Int; 2020; 2020():1563874. PubMed ID: 32832543
[TBL] [Abstract][Full Text] [Related]
7. Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
Zhang D; Raghavan N; Chen SY; Zhang H; Quan M; Lecureux L; Patrone LM; Lam PY; Bonacorsi SJ; Knabb RM; Skiles GL; He K
Drug Metab Dispos; 2008 Feb; 36(2):303-15. PubMed ID: 17984286
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study.
Li SL; Zhu YL; Zhu CY; Li SB; Li ZH; Qiu XJ
Drug Des Devel Ther; 2020; 14():1117-1125. PubMed ID: 32214797
[TBL] [Abstract][Full Text] [Related]
9. Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children.
Hullett B; Salman S; O'Halloran SJ; Peirce D; Davies K; Ilett KF
Anesthesiology; 2012 May; 116(5):1124-33. PubMed ID: 22450476
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats.
Kim TW; Vercelli C; Briganti A; Re G; Giorgi M
Vet J; 2014 Oct; 202(1):37-42. PubMed ID: 25135338
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.
Pavan Kumar VV; Vinu MC; Ramani AV; Mullangi R; Srinivas NR
Biomed Chromatogr; 2006 Jan; 20(1):125-32. PubMed ID: 16013036
[TBL] [Abstract][Full Text] [Related]
12. A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma.
Werner U; Werner D; Hinz B; Lambrecht C; Brune K
Biomed Chromatogr; 2005 Mar; 19(2):113-8. PubMed ID: 15473012
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
Johnson KA; Prakash C
Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects.
Karim A; Laurent A; Slater ME; Kuss ME; Qian J; Crosby-Sessoms SL; Hubbard RC
J Clin Pharmacol; 2001 Oct; 41(10):1111-9. PubMed ID: 11583480
[TBL] [Abstract][Full Text] [Related]
15. Collision-induced dissociation of valdecoxib metabolites: a novel rearrangement involving an isoxazole ring.
Zhang JY; Xu F; Breau AP
J Mass Spectrom; 2004 Mar; 39(3):295-302. PubMed ID: 15039937
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
Tiseo PJ; Perdomo CA; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
18. Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study.
Keshetty S; Venisetty RK; Molmoori V; Ciddi V
Pharmazie; 2006 Mar; 61(3):245-6. PubMed ID: 16599270
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism.
Bhamidipati R; Mujeeb S; Dravid PV; Khan AA; Singh SK; Rao YK; Mullangi R; Srinivas NR
Xenobiotica; 2005 Mar; 35(3):253-71. PubMed ID: 16019950
[TBL] [Abstract][Full Text] [Related]
20. An effective dose of valdecoxib in experimental mouse models of pain.
Guo CX; Irwin MG; Cheung KM; Chan D
Methods Find Exp Clin Pharmacol; 2007; 29(6):383-8. PubMed ID: 17922065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
